Loren Walensky of the Dana-Farber Cancer Institute in the U.S. will apply a new chemical technology to engineer structurally stable HIV-1 antigens for vaccine development. Walensky will test whether preserving the critical biologically active shape of HIV-1 polypeptides will yield neutralizing antibodies upon vaccination with his laboratory's synthetic immunogens.
Grant ID
OPP53084
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False